Expert insights. Personalized for you.
Sales Related Topics 
Bio Pharma Dive
JULY 21, 2021
billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks The pharmaceutical company expects $2.5
Pharma Phorum
OCTOBER 13, 2021
Create and disseminate sales support materials. Manage and develop sales team (sales manager role only). Proven experience of working as part of a sales team. Proven work experience working in a sales-based role. The post Sales manager appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MAY 4, 2022
The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S.
Bio Pharma Dive
FEBRUARY 5, 2021
Sales of the antiviral drug accounted for a quarter of the biotech's product revenue in the fourth quarter, disguising hits to its business elsewhere
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Bio Pharma Dive
DECEMBER 22, 2021
Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness
Bio Pharma Dive
APRIL 28, 2022
Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs
Bio Pharma Dive
FEBRUARY 3, 2022
Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage
Bio Pharma Dive
FEBRUARY 10, 2022
The biotech is predicting sales of Tukysa, its new breast cancer drug, will remain flat or fall in 2022 as competition increases from AstraZeneca's rival medicine Enhertu
Bio Pharma Dive
OCTOBER 18, 2021
The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines
Bio Pharma Dive
MAY 5, 2022
The biotech reported positive results from a study meant to expand Vyvgart's use to another immune disorder, while sales from the drug's first quarter on the market exceeded expectations
Bio Pharma Dive
OCTOBER 28, 2021
But sales could climb even higher if it works as a preventive treatment too Executives based their projections on contracts already in place for the drug, known as molnupiravir.
Pharma Phorum
JUNE 6, 2022
Eversana’s suite of commercialisation tools for pharma companies will soon have a new component – cognitive behavioural training tools designed to improve the performance of sales representatives. Digital News Sales and Marketing digital Sales reps Training
|
Bio Pharma Dive
APRIL 29, 2021
Both companies blamed the impact of COVID-19 on sharp declines in sales of their shingles, pneumonia and HPV shots
Bio Pharma Dive
FEBRUARY 8, 2022
The company estimated revenue from its COVID-19 vaccine and antiviral pill Paxlovid will total $54 billion this year. Curiously, its stock fell by more than 5
Bio Pharma Dive
FEBRUARY 2, 2021
The estimate for 2021 sales, which Pfizer splits with partner BioNTech, would make the vaccine one of the highest-selling medicines in the industry
Bio Pharma Dive
NOVEMBER 2, 2021
The drugmaker again increased its forecast for 2021 sales, this time to $36 billion, or about 80% of what the rest of Pfizer's business is expected to earn this year
Bio Pharma Dive
JULY 31, 2020
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations
Bio Pharma Dive
JULY 8, 2021
Second quarter sales of Nurtec ODT, which recently became the first migraine drug cleared for acute and preventive treatment, were nearly twice what analysts on Wall Street had predicted
Bio Pharma Dive
FEBRUARY 9, 2022
Facing falling sales of top-seller Enbrel, the biotech tried to shore up confidence in its ability to grow new products, like the cancer drug Lumakras
Pharma Phorum
NOVEMBER 9, 2021
COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment of how the sales function should work. The industry faces the dawn of a new age in sales coaching.
Bio Pharma Dive
MARCH 15, 2022
Instead of sharing global profits and losses, Eisai will receive royalties tied to net sales of the Alzheimer's drug. Biogen, meanwhile, said the amended deal should make it easier to "address market developments "
Bio Pharma Dive
MAY 25, 2022
The pharma has been criticized for not doing enough to make its COVID-19 vaccine and pill available globally. The new initiative commits Pfizer to supplying current and future branded medicines at lower cost to 45 countries
Scienmag
MAY 12, 2022
ATLANTA, May 12, 2022 – New research led by scientists at the American Cancer Society (ACS) shows the need for continued surveillance of the changes in shopping interest and sales for Puff Bar, the most preferred brand of electronic cigarettes or e-cigarettes among youth in the United States.
Bio Pharma Dive
FEBRUARY 17, 2021
The Swiss drugmaker's pill Entresto is now cleared in the U.S. for use in patients with stronger hearts, expanding the eligible population by two-thirds
Cloudbyz
MARCH 24, 2022
Tuesday, March 22nd Cloudbyz joined Salesforce at their Chicago offices for a joint sales enablement event discussing both the clinical trial space and how Salesforce and Cloudbyz solutions help life science organizations get their products to market faster.
Bio Pharma Dive
SEPTEMBER 30, 2021
The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts
Pharma Phorum
APRIL 27, 2022
GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. billion with no sales recorded in the prior year. News Sales and Marketing GlaxoSmithKline Shingrix xevudy
Pharma Phorum
MARCH 18, 2021
The demise of the pharmaceutical sales representative has been greatly exaggerated over the years. The current restrictions on face-to-face meetings have exacerbated the trend of sales reps’ reduced access to healthcare customers.
BioSpace
JUNE 21, 2022
BioSpace spoke with Jay Johnson, the Director of Talent Acquisition for Orthopedics at Stryker, to find out what it takes to land a job in medical sales
Bio Pharma Dive
NOVEMBER 4, 2021
The biotech now expects to deliver between 700 million and 800 million doses this year, down from a previous forecast of 800 million to 1 billion
Bio Pharma Dive
OCTOBER 6, 2021
The neuroscience-focused biotech continues to win market share in a battle with some of the industry's largest companies
Bio Pharma Dive
OCTOBER 26, 2021
The generic drug unit has struggled in recent years, while Novartis has moved to focus more narrowly on higher-margin branded medicines
Bio Pharma Dive
OCTOBER 19, 2021
The drugmaker plans to switch over to a commercial business model late next year or early in 2023, said Jennifer Taubert, head of J&J's pharma division
Pharma Phorum
MARCH 14, 2022
Analysts have suggested its financial troubles could make a sale more difficult, as could untangling Sandoz from Novartis’ broader manufacturing operations, although the launch of new biosimilars next year could help lift margins.
Pharma Marketing Network
APRIL 21, 2021
The Pharma Marketing Podcast is pleased to present this special guest episode from our friend and Editorial Advisory Board member Darshan Kulkarni, Sales and Marketing Oversight – April 21, 2021. [link].
Pharma Phorum
FEBRUARY 9, 2022
There was another £447 million from sales of GSK’s adjuvant, used to boost the efficacy of other companies’ COVID-19 shots, although the company’s own efforts to develop a jab have so far been unsuccessful. Last year, sales at the JV stabilised at £9.6
Pharma Phorum
FEBRUARY 3, 2022
Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit may not come until the last quarter of the year.
Bio Pharma Dive
APRIL 19, 2022
The drugmaker previously expected up to $3.5 billion in 2022 revenue, but uncertainty about the pace of vaccinations led it to suspend investor guidance
Bio Pharma Dive
MAY 13, 2022
The drugmaker was able to get $110 million for its voucher, a kind of regulatory fast pass. Other vouchers have sold for similar amounts, boding well for Bluebird, which plans to sell two that it hopes to get this year
Scienmag
DECEMBER 9, 2021
Social & Behavioral Science change employee Increasing Overcoming resistance sales secret Service storytelling weaponWith the increasing digitalization in manufacturing industries, companies start to integrate big data analytics into business processes and sell smart services.
Pharma Phorum
FEBRUARY 18, 2022
Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours.
Bio Pharma Dive
MAY 4, 2022
Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S. revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread
247 
Let's personalize your content